A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hypercholesterolemic patients.

Siddhartha DuttaRima ShahShubha SinghalSurjit SinghKiran PiparvaChandan Dev Singh Katoch

Published in: Expert opinion on drug safety (2023)

The pooled analysis of the existing evidence shows that inclisiran showed reduced risk of MACE along with excellent efficacy in managing dyslipidemia.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
left ventricular
stem cells
double blind
phase iii
patient reported
placebo controlled